Photo credit: www.investing.com
PacBio Launches New Vega Long-Read Sequencing System
MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leader in advanced sequencing technologies, unveiled its latest innovation, the Vega system. This new benchtop long-read sequencing platform combines the capabilities of the existing Revio system, renowned for its high throughput, into a more compact and user-friendly format designed for lower throughput.
The Vega system boasts impressive features, including high fidelity data accuracy with HiFi technology and rapid processing times. Priced at $169,000, it aims to provide an accessible option for researchers engaged in various sequencing applications such as targeted sequencing, RNA sequencing, and small genome analysis.
“With the introduction of the Vega system, we are fulfilling our commitment to make advanced sequencing technologies more widely available, balancing affordability with high precision,” stated Christian Henry, PacBio’s President and CEO. He emphasized that the launch reflects the company’s strategy to continuously innovate and cater to the diverse demands of the research community, particularly following the successful introduction of Revio in early 2023.
Vega is designed to integrate seamlessly into the existing HiFi ecosystem, facilitating library preparation and data analysis for researchers pursuing HiFi sequencing strategies. Each run utilizes one SMRT cell, enabling an impressive throughput of 600 full-length RNA samples annually using the Kinnex full-length RNA kit, or up to 200 human genomes.
Dr. Aiping Mao, Vice Director of Berry Genomics R&D, shared insights from their preliminary tests with the Vega system, noting its speed and straightforward operation. He highlighted its cost-effective target sequencing functionalities and rapid sequencing runs, making it particularly suitable for clinical laboratory-developed test (LDT) applications within China.
At the New York Center for Rare Diseases, Dr. John M. Greally underscored the significance of HiFi long-read sequencing for rare disease research. He remarked that the Vega system enhances the technology’s accessibility, granting more scientists and institutions the capability to investigate complex cases that elude traditional methods.
Vega not only aims to democratize HiFi long-read sequencing but also features robust onboard computing capabilities akin to other PacBio instruments. The user-friendly design requires only two consumables for operation, thus streamlining the workflow. Additionally, PacBio is offering SMRT Link Cloud software, enabling remote instrument management without the necessity for extensive local computing resources.
Britt Johnson, PhD, FACMG and Head of Medical Affairs at GeneDx, expressed excitement about the potential of the new Vega sequencer to enhance their HiFi sequencing capacity. She noted that the more manageable size and reduced cost would allow for greater incorporation of this transformative technology in their research, ultimately benefiting more patients.
Orders for the Vega system are currently being accepted, with shipments expected to begin in the first quarter of 2025. The system will be showcased at the upcoming American Society of Human Genetics annual meeting in Denver, Colorado, where attendees can visit PacBio’s booth for more information.
About PacBio
PacBio (NASDAQ: PACB) specializes in life science technology, focusing on developing advanced sequencing solutions that address complex genetic challenges. The company relies on two primary technologies—HiFi long-read and SBB® short-read sequencing—allowing a wide range of applications, from human genetics to plant science and oncology. More details can be found at www.pacb.com and on their Twitter page, @PacBio.
PacBio products are strictly for research purposes only and are not intended for diagnostic applications.
Forward Looking Statements
This release may contain forward-looking statements as defined by U.S. securities laws. These statements involve risks and uncertainties that might cause actual outcomes to differ significantly from those anticipated, including challenges in product development and market acceptance. A comprehensive understanding of these risks is critical and can be reviewed in PacBio’s latest filings with the Securities and Exchange Commission.
Source
www.investing.com